Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02077959 | Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM(ANCHOR) | terminated | Phase 1 / Phase 2 | 56 | Oncopeptides ABINDUSTRY | 4 | Dec 19, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 22 | AmgenINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 210 | AmgenINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 6 | Hangzhou Zenshine Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant | terminated | Phase 1 | 6 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | terminated | Phase 1 | 18 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 136 | Criterium, Inc.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | terminated | Phase 1 | 2 | Eden BioCell Ltd.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | terminated | Phase 1 | 10 | TG Therapeutics, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04115956 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | terminated | Phase 1 | 6 | Oncopeptides ABINDUSTRY | 9 | Mar 28, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
| NCT02998047 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | terminated | Phase 1 | 2 | Actinium PharmaceuticalsINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | terminated | Phase 1 | 4 | Klinikum StuttgartOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | terminated | Phase 1 | 7 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | terminated | Phase 1 | 9 | AbbVieINDUSTRY | 3 | Dec 7, 2021 | clinicaltrials |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | terminated | Phase 1 | 13 | ADC Therapeutics S.A.INDUSTRY | 2 | Oct 26, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | terminated | Phase 1 | 12 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04730505 | A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM(MyHOPE™) | terminated | Phase 1 | 2 | CelgeneINDUSTRY | 1 | Aug 9, 2021 | clinicaltrials |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT03892525 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma | terminated | Phase 1 | 4 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma | terminated | Phase 1 | 8 | AbbVieINDUSTRY | 7 | Jul 26, 2021 | clinicaltrials |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | terminated | Phase 1 / Phase 2 | 13 | RedHill Biopharma LimitedINDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | terminated | Phase 1 / Phase 2 | 6 | Mundipharma-EDO GmbHINDUSTRY | 3 | Jun 18, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01999335 | A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 33 | AmgenINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | terminated | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | terminated | Phase 1 | 77 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 8, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 21 | Chinook Therapeutics, Inc.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | terminated | Phase 1 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | terminated | Phase 1 / Phase 2 | 25 | Acerta Pharma BVINDUSTRY | 2 | Jan 6, 2021 | clinicaltrials |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | terminated | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 19, 2020 | clinicaltrials |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | terminated | Phase 1 | 5 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT02151903 | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL | terminated | Phase 1 / Phase 2 | 5 | Alopexx Oncology, LLCINDUSTRY | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01874288 | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL(DI-Leu16-IL2) | terminated | Phase 1 / Phase 2 | 24 | Alopexx Oncology, LLCINDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2023source: clinicaltrials